While former FDA official Vinay Prasad was known for his stringent reviews, the continued institutional skepticism towards Capricor's drug after his departure suggests the concerns were widespread among FDA staff. This indicates that attributing the FDA's recent restrictive stance solely to one individual's leadership style is an oversimplification of the agency's internal consensus on data quality.

The FDA publicly champions rare disease drug development, but its actions—frequent and inconsistent rejections—tell a different story. This disconnect between rhetoric and reality creates significant uncertainty, causing prominent investors like Rod Wong of RTW Investors to reduce their investments in the space.

Despite celebrating groundbreaking Huntington's data, veteran advocate Lauren Holder immediately advised her community to "be prepared for a fight." This highlights a key trait of mature advocacy: tempering excitement with the realistic expectation of facing significant regulatory and access challenges, even after positive clinical results are announced.

The FDA panel's stringent data requirements for Capricor's Duchenne drug for older boys highlights a perceived regulatory inconsistency. This tough stance contrasts with previous accelerated approvals for Sarepta's Duchenne therapies, which were granted despite unproven efficacy. This raises questions about whether the agency applies different standards to similar patient populations over time.

The FDA's conflict with Unicure over its Huntington's gene therapy highlights a significant philosophical shift. New leadership is demanding rigorous sham-controlled trials, involving drilling into patients' skulls for a placebo, a stark contrast to the previous, more flexible regime. This signals a much higher, potentially prohibitive, evidence bar for future gene therapies.

The FDA's traditional focus on risk avoidance overlooks the inherent risk of delay. Unnecessary bureaucratic steps, like months of animal trials, prevent dying patients from accessing potentially life-saving treatments. The cost of inaction is measured in lives lost.

The current disconnect between the FDA leadership's public calls for flexibility and its divisions' strict actions is not new. For decades, the agency's hierarchy has acted as a promotional arm to encourage industry, while the review divisions have maintained a more conservative, old-school approach to rigor. This historical pattern is often overlooked.

The FDA's current leadership appears to be raising the bar for approvals based on single-arm studies. Especially in slowly progressing diseases with variable endpoints, the agency now requires an effect so dramatic it's akin to a parachute's benefit—unmistakable and not subject to interpretation against historical data.

For fatal, untreatable diseases, the choice is not between a risky drug and a safe baseline. The paradigm shifts to a "risk-risk" choice: the risk of an experimental therapy versus the risk of doing nothing, which is certain death. This reframes the ethical calculus for regulators and developers.